05 Aug 21 | A new study reported that the safety profiles and pharmacokinetic parameters of Amgen’s ABP980 (biosimilar...
Home / News / Pearce IP Blog
ALL BLOGS BY
Naomi Pearce
PTEs in Australia – hard lessons for patentees from the Federal Court
Date: 12 August 2021Court: Federal Court of AustraliaJudge: Jagot J Background Under Australian law, a patent term...
Pearce IP BioBlast®: w/e 06 August 2021
29 Jul 21 | US | The American Academy of Ophthalmology pushed back against insurance company pressure to use new...
Pearce IP BioBlast®: w/e 30 July 2021
27 Jul 21 | Abenza and BioXpress Therapeutics announced they have formed a new partnership to support biosimilar...
Pearce IP BioBlast®: w/e 23 July 2021
19 Jul 21 | Shanghai Henlius Biotech announced that the first patient has been dosed in its Ph I clinical trial of...
Blockchain technology gets a nod as patentable subject matter
Date: 21 July 2021Forum: Australian Patent OfficeDelegate: Ranganath Subbarayan Background Australian Patent...
Pearce IP BioBlast®: w/e 16 July 2021
12 Jul 21 | Boditech Med announced it has obtained export approval for AFIAS Adalimumab, a diagnostic kit which...
Pearce IP BioBlast®: w/e 09 July 2021
05 Jul 21 | Chong Kun Dang announced it has signed a commercialisation agreement with Menagen for Nesbell® (biosimilar...
Let the applicant beware!
Although Australia has taken steps in recent years to harmonise its patent laws with those around the globe,...
Pearce IP BioBlast®: w/e 02 July 2021
27 Jun 21 | CN | Innovent Biologics announced China’s National Medical Products Administration has approved its...
Sisters are doin’ it for themselves: female inventors more likely to invent for women
A new report demonstrates that female-dominated inventor teams in biomedical sciences are more likely to invent...
Words matter – Specification guides claim construction
Date: 30 June 2021Court: Full Court of the Federal Court of AustraliaJudges: Yates, Moshinsky and Burley JJ Background...
Pearce IP BioBlast®: w/e 25 June 2021
23 Jun 21 | US | Genentech announced that the FDA has accepted the BLA for its Port Delivery System with ranibizumab...
Diagnostic tests that rely on a naturally occurring phenomenon patent eligible in Australia
Diagnostic tests that rely on a naturally occurring phenomenon patent eligible in Australia On 18 June 2021, the Full...
Correspondence lost to spam filter justifies extension of time
Date: 22 June 2021Forum: Australian Patent OfficeDelegate: Xavier Gisz Background As part of the Raising the Bar...
Pearce IP BioBlast®: w/e 18 June 2021
10 June 21 | The UK's NICE published final draft guidance recommending adalimumab, etanercept and infliximab for the...